Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-76231 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PLCXD2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells.
Liu Z, Hu K, Wang X, Zhang Y, Wang W, Wu Y
Open medicine (Warsaw, Poland) 2022;17(1):266-279
Open medicine (Warsaw, Poland) 2022;17(1):266-279
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of PLCXD2 in extracts of various cell lines. Samples were incubated with PLCXD2 polyclonal antibody (Product # PA5-76231).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of FANCM in A549 cells. Samples were incubated with FANCM polyclonal antibody (Product # PA5-76229).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of PLCXD2 in A549 cells. Samples were incubated with PLCXD2 polyclonal antibody (Product # PA5-76231).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 ACTA2-AS1 upregulates PLCXD2 expression by binding with miR-378a-3p. (a) Knockdown efficiency of miR-378a-3p inhibitor in SGC7901 and AGS cells was examined using RT-qPCR. (b) Nine mRNAs containing binding site with miR-378a-3p were predicted with miRDB. RT-qPCR was employed to detect the effect of miR-378a-3p inhibition on the expression of these candidate mRNAs. (c) The expression of PLCXD2 in STAD tissues ( n = 408) and normal tissues ( n = 211) was analyzed by GEPIA. (d) Subcellular fractionation assays were performed to detect the primary localization of PLCXD2. (e) The impacts of ACTA2-AS1 overexpression on mRNA and protein levels of PLCXD2 were measured by RT-qPCR and Western blot. (f) Western blot was conducted to detect protein level of PLCXD2 in GC cells transfected with miR-378a-3p inhibitor or NC inhibitor. (g) The binding site between miR-378a-3p and PLCXD2 was predicted from miRDB website. (h-j) Luciferase reporter assays and RIP assays were applied to explore the relationship among ACTA2-AS1, miR-378a-3p, and PLCXD2. *** p < 0.001.